In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...